Urothelial Cancer | Specialty

The OncLive Urology condition center page is a comprehensive resource for clinical news and expert insights on urologic cancers, including prostate cancer, bladder cancer, testicular cancer, penile cancer, and renal cell carcinoma. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in brain cancer.

TAR-200 Monotherapy Is Effective and Well Tolerated in BCG-unresponsive NMIBC

October 24th 2023

The intravesical chemotherapy delivery system TAR-200 provided sustained and durable responses in patients with Bacillus Calmette-Guérin–unresponsive, high-risk, non–muscle-invasive bladder cancer.

Frontline Enfortumab Vedotin Plus Pembrolizumab Elicits OS Improvement in Advanced Urothelial Carcinoma

October 22nd 2023

Frontline treatment with the combination of enfortumab vedotin-ejfv and pembrolizumab led to a statistically significant improvement in overall survival vs chemotherapy in patients with previously untreated locally advanced or metastatic urothelial carcinoma.

Frontline Nivolumab Plus Chemotherapy Boosts OS and PFS in Metastatic Urothelial Carcinoma

October 22nd 2023

Concurrent frontline nivolumab and gemcitabine-cisplatin followed by nivolumab maintenance therapy elicited OS and PFS benefits vs gemcitabine-cisplatin alone in patients with previously untreated, metastatic or unresectable urothelial carcinoma.

Dr Pagliaro on the Use of First-Line Avelumab Maintenance Therapy in Urothelial Carcinoma

October 20th 2023

Lance C. Pagliaro, MD, discusses the efficacy of first-line avelumab maintenance therapy, as seen in the phase 3 JAVELIN Bladder 100 trial in patients with advanced urothelial carcinoma.

Dr Bilusic on Updates to the Urothelial Carcinoma Treatment Armamentarium

October 20th 2023

Marijo Bilusic, MD, PhD, discusses updates seen in the treatment armamentarium for patients with urothelial carcinoma, as presented at the 2023 Sylvester Annual Oncology Updates Meeting.

Individualized Treatment Selection and Sequencing Enhances Bladder and Prostate Cancer Management

October 18th 2023

Daniel S. Childs, MD, and colleagues spotlight future innovations in the management of metastatic hormone-sensitive prostate cancer, treatment sequencing for metastatic urothelial carcinoma, and key data with PARP inhibitor combinations in metastatic castration-resistant prostate cancer.

Dr Wang on Testing for Molecular Alterations in Relapsed/Refractory Urothelial Carcinoma

October 17th 2023

Jue Wang, MD, discusses how to approach testing for molecular alterations in patients with relapsed or refractory urothelial carcinoma.

Dr Wang on the Importance of Personalized Treatment Approaches in Urothelial Cancer

October 13th 2023

Jue Wang, MD, discusses the importance of personalized treatment approaches in patients with relapsed or refractory urothelial carcinoma.

State of the Science Summit - Bladder/Prostate Cancer: Chaired by Arpita Desai, MD and Rahul Aggarwal, MD

October 13th 2023

State of the Science Summit - Bladder/Prostate Cancer: Chaired by Arpita Desai, MD and Rahul Aggarwal, MD

Adjuvant Pembrolizumab Improves DFS in Localized Urothelial Cancer

October 5th 2023

Pembrolizumab as adjuvant therapy led to a statistically significant and clinically meaningful improvement in disease-free survival compared with observation in patients with localized muscle invasive urothelial cancer and locally advanced urothelial cancer.

Dr Desai on the Benefits and Limitations of Bladder Preservation With Chemoradiation in MIBC

September 28th 2023

Neil Desai, MD, discusses the potential benefits and limitations of utilizing chemoradiation or triple modality therapy for bladder preservation in the upfront management of patients with locally advanced, nonmetastatic muscle-invasive bladder cancer.

Enfortumab Vedotin Plus Pembrolizumab Generates Survival Benefit in Previously Untreated Advanced Urothelial Cancer

September 22nd 2023

Treatment with the combination of enfortumab Vedotin and pembrolizumab led to an improvement in overall survival and progression-free survival compared with chemotherapy in previously untreated patients with locally advanced or metastatic urothelial cancer who were eligible for cisplatin- or carboplatin-containing chemotherapy.

State of Science Summit- Bladder/Prostate Cancers: Chaired by Vivek K. Narayan, MD, MS

September 21st 2023

State of Science Summit- Bladder/Prostate Cancers: Chaired by Vivek K. Narayan, MD, MS

Dr Petrylak on the Potential Use of Erdafitinib in Metastatic Urothelial Cancer

September 15th 2023

Daniel P. Petrylak, MD, discusses the potential uses for erdafitinib, highlighting key studies evaluating the use of the agent in patients with metastatic urothelial cancer.

Preoperative APL-1202 Plus Tislelizumab Meets pCR Criteria, Moves to Next Stage of Trial in MIBC

September 13th 2023

The Safety Monitoring Committee determined that prespecified criteria for pathologic complete response were met with the use of the PD-1 inhibitor tislelizumab alone or in combination with APL-1202 as neoadjuvant therapy in patients with muscle invasive bladder cancer.

European Approval Sought for Erdafitinib in Locally Advanced or Metastatic FGFR3+ Urothelial Carcinoma

September 12th 2023

A marketing authorization application has been submitted to the European Medicines Agency seeking the approval of erdafitinib for the treatment of adult patients with locally advanced, unresectable or metastatic urothelial carcinoma harboring susceptible FGFR3 alterations who experienced disease progression during or following at least 1 line of therapy containing a PD-1/PD-L1 inhibitor.

Dr Wang on Switch Maintenance Therapy in Urothelial Carcinoma

September 6th 2023

Jue Wang, MD, professor, Department of Internal Medicine, member, Division of Hematology and Oncology, UT Southwestern Medical Center, discusses the benefits of switch maintenance therapy and individualized treatment strategies in patients with relapsed or refractory urothelial carcinoma.

Perioperative Durvalumab Plus SOC Shows Promising EFS Results in Muscle-Invasive Urothelial Carcinoma

August 31st 2023

Treatment with neoadjuvant durvalumab plus gemcitabine and cisplatin followed by radical surgery and adjuvant durvalumab for patients with muscle-invasive urothelial carcinoma resulted in 2-year event-free survival rates that met the primary end point of the phase 2 SAKK 06/17 trial.

Treatment Sequencing in Refractory Urothelial Carcinoma Requires a Personalized Approach

August 30th 2023

Jue Wang, MD, highlights key takeaways regarding treatment sequencing for patients with relapsed/refractory urothelial carcinoma and the key factors that could help inform decisions for individual patients.

FDA Approval Sought for Erdafitinib in Locally Advanced or Metastatic FGFR3+ Urothelial Carcinoma

August 29th 2023

A supplemental new drug application seeking the full approval of erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma harboring susceptible FGFR3 alterations who progressed during or following at least 1 line of a PD-1/PD-L1 inhibitor in the locally advanced or metastatic setting or within 12 months of neoadjuvant or adjuvant therapy, has been submitted to the FDA.